オプションチェーンは、Elicio Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Elicio Therapeuticsの市場センチメントを評価します。.

Elicio Therapeutics (NASDAQ:ELTX) 株価情報, オプションチェーン

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Elicio Therapeutics Inc

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 11.44% on an annualized basis producing an average annual return of 21.65%. Currently, Meta Platforms has a market capitalization of $1.39 trillion. 
Buying $1000 In META: If an investor had bought $1000 of META stock 10 years ago, it would be worth $6,983.12 today based on a price of $550.34 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745941512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Meta Platforms 10 Years Ago Would Be Worth This Much Today

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Principal Financial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) with a Market Perform and lowers the price target from $88 to $86.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Market Perform on Principal Financial Group, Lowers Price Target to $86

WIIM

FISI

Financial Institutions shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Over the past three weeks, shares of Progressive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) have declined by 8%, <a href="https://www.benzinga.com/topic/s-p-500">underperforming the S&amp;P 500</a> by more than 1,000 basis points, according to BofA Securities.
The Progressive Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8bb85e9300015f1ad8/joshua-shanker">Analyst Joshua Shanker</a> upgraded the rating from Neutral to Buy, while raising the price target from $297 to $312.
The Progressive Thesis: Earlier this month, the company announced its March 2025 results, adding a net 572,000 new personal auto customers, representing a month of the highest growth in its history, Shankar said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
"It remains to be seen to what degree tariffs will be implemented by the Trump administration, creating uncertainty," the analyst wrote.
Shankar pointed out that supply-chain disruptions during the pandemic and post-pandemic periods resulted in the steepest auto insurance price hikes in 50 years, boosting profitability and market share gains for Progressive. Similarly tariff-induced inflation may act as "a tailwind to Progressive&#8217;s success and PGR stock performance," he further stated.
PGR Price Action: Shares of Progressive had risen by 1.7% to $274.19 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwj2hvfI_fqMAxXER2wGHWLEOIsQxfQBKAB6BAgJEAE&amp;url=https%3A%2F%2Fwww.benzinga.com%2Fnews%2Fearnings%2F25%2F04%2F44937938%2Fcapital-one-reports-mixed-q1-results-eps-beat-revenue-misses&amp;usg=AOvVaw3g8PTc3dpKR3V3BTnwdyaP&amp;opi=89978449">Dividend Investor Making $6,000/Month Shares Portfolio; Bought More on Recent &#8216;Bloody Day&#8217; Selloff — &#8216;Keep Grinding Until We Don&#8217;t Have To&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Upgrades

Movers

Progressive's Pain May Turn To Gain As Tariff Inflation Creates A Surprising Tailwind

Universal Logistics shares are trading lower after Stifel cut its price target on the stock from $37 to $29.

TD Cowen analyst Derick Ma initiates coverage on Faraday Copper (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FDY#TSX">FDY</a>) with a Buy rating and announces Price Target of C$1.25.

Initiation

TSX:FDY

TD Cowen Initiates Coverage On Faraday Copper with Buy Rating, Announces Price Target of C$1.25

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains PCB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCB#NASDAQ">PCB</a>) with a Market Perform and raises the price target from $21 to $23.

Keefe, Bruyette & Woods Maintains Market Perform on PCB Bancorp, Raises Price Target to $23

Scotiabank analyst Brandon Bingham maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Sector Outperform and lowers the price target from $201 to $199.

TRGP

Scotiabank Maintains Sector Outperform on Targa Resources, Lowers Price Target to $199

MBIN

Merchants Bancorp shares are trading lower after the company reported worse-than-expected Q1 financial results.

Glass Lewis Opposes Removal of Barnwell Board Members Ken Grossman, Josh Horowitz and Alex Kinzler
Barnwell Shareholders Should Ignore and Discard Any Blue Consent Solicitation Card
Shareholders Who Sent a Blue Consent Solicitation Card Can Revoke Their Vote by&nbsp;Sending the Company's White Card
HONOLULU, Hawaii, April 29, 2025 /PRNewswire/ -- Barnwell Industries, Inc. ("Barnwell" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRN#NYSE">BRN</a>) today announced that Glass Lewis, a leading independent proxy advisory firm, has resoundingly rejected the Sherwood Group's efforts to take control of the Company and declared the removal of Barnwell directors Ken Grossman, Josh Horowitz and Alex Kinzler to be unwarranted.

Proxy Advisory Firm Glass Lewis Rejects Sherwood Group's Efforts To Take Control Of Barnwell Control

Keefe, Bruyette &amp; Woods analyst Christopher O'Connell maintains Northfield Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFBK#NASDAQ">NFBK</a>) with a Market Perform and lowers the price target from $12.5 to $12.

NFBK

Keefe, Bruyette & Woods Maintains Market Perform on Northfield Bancorp, Lowers Price Target to $12

ALRS

Alerus Financial shares are trading higher after the company reported better-than-expected Q1 financial results.

Scotiabank analyst Brandon Bingham maintains ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) with a Sector Outperform and lowers the price target from $101 to $100.

Scotiabank Maintains Sector Outperform on ONEOK, Lowers Price Target to $100

TriMas shares are trading higher after the company reported better-than-expected Q1 financial results.

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith maintains MBIA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBI#NYSE">MBI</a>) with a Outperform and lowers the price target from $9 to $8.

Keefe, Bruyette & Woods Maintains Outperform on MBIA, Lowers Price Target to $8

TD Cowen analyst Derick Ma initiates coverage on Arizona Sonoran Copper (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ASCU#TSX">ASCU</a>) with a Buy rating and announces Price Target of C$4.25.

TSX:ASCU

TD Cowen Initiates Coverage On Arizona Sonoran Copper with Buy Rating, Announces Price Target of C$4.25

KFRC

Kforce shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 EPS guidance below estimates.

Daqo New Energy shares are trading lower after the company reported worse-than-expected Q1 financial results.

Keefe, Bruyette &amp; Woods analyst Christopher O'Connell maintains Kearny Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNY#NASDAQ">KRNY</a>) with a Market Perform and lowers the price target from $7.25 to $7.

KRNY

Keefe, Bruyette & Woods Maintains Market Perform on Kearny Financial, Lowers Price Target to $7

ACMR

ACM Research shares are trading lower after the company provide preliminary Q1 financial results.

Press Releases

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Health Care

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting

Earnings

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

General

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Financing

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Management

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

ELTX

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Agenus

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Biomea Fusion

Climb Bio

Caribou Biosciences

CervoMed

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Seres Therapeutics

MediciNova

Sutro Biopharma

Instil Bio

Tenaya Therapeutics

Vigil Neuroscience

Vor Biopharma

Whitehawk Therapeutics, Inc. - Common Stock

Comments

Elicio Therapeutics

Elicio Therapeutics (ELTX) オプション

Elicio Therapeutics (NASDAQ:ELTX) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル